Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489941 | 1.00 | OGA (0.34) | OGACA9CA12CA1CA2 | |
| SCHEMBL16489936 | 0.91 | CA9 (0.33) | OGACA9CA12CA1CA2 | |
| SCHEMBL16489938 | 0.87 | CA9 (0.41) | OGACA9CA12CA1CA2 | |
| SCHEMBL15975384 | 0.86 | CA9 (0.41) | OGACA9CA12CA1CA2 | |
| SCHEMBL17281224 | 0.83 | CA9 (0.40) | OGACA9CA12CA1CA2 | |
| SCHEMBL26243889 | 0.83 | CA9 (0.40) | OGACA9CA12CA1CA2 | |
| SCHEMBL26499249 | 0.83 | CA9 (0.40) | OGACA9CA12CA1CA2 | |
| SCHEMBL26483823 | 0.81 | CA9 (0.39) | OGACA9CA12CA1CA2 | |
| SCHEMBL16489948 | 0.81 | CA9 (0.39) | OGACA9CA12CA1CA2 | |
| SCHEMBL26635308 | 0.81 | CA9 (0.39) | OGACA9CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | INSTITUT PASTEUR (FR) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | ST3GAL3, SI, STT3A | OGA 166/4885CA9 1476/4885CA12 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.